Iantrek Secures $30M in Growth Funding to Expand Bio-Interventional Glaucoma Treatment Platform

Precision in medicine used to mean steady hands and repetition. Now it’s starting to look a lot more like engineered intent… calculated, data-backed, and just disruptive enough to make the old guard uncomfortable. Iantrek, the White Plains, New York based medtech company building inside the world of bio-interventional ophthalmic surgery, just pulled in $30M in growth capital from Trinity Capital Inc. You can call it venture debt if you want to sound polished. I call it fuel with expectations attached. Either way, it’s capital aimed straight at scale.

Credit where it’s due. Adam Szaronos, CEO, stepping in and driving commercial momentum, paired with Dr. Tsontcho Ianchulev, the founder who’s been engineering ophthalmic innovation longer than most people have been spelling “ophthalmology” correctly. That combination tends to make investors pay attention, and Trinity Capital did exactly that.

Now here’s where it gets interesting. Iantrek isn’t playing the usual hardware game inside glaucoma. No metal left behind, no shortcuts through biology. Their BIOS platform leans into allogeneic bio-tissue, working with the eye’s natural outflow pathways instead of bulldozing past them. AlloFlo Uveo, their lead product launched in October 2025, is already moving through the market with over 2,000 procedures completed before most companies would even finish their launch deck.

The numbers whisper, but they carry weight. Meaningful intraocular pressure reduction, fewer medications, and a hardware-free approach in a space that’s been comfortable installing permanent solutions. Surgeons get precision without compromise. Patients get outcomes without extra baggage. That’s not marketing spin, that’s positioning.

And then there’s timing. Over 2.5M eyes in the U.S. alone are dealing with diminishing returns from existing MIGS procedures. The market isn’t just large, it’s waiting. Global glaucoma numbers climbing past 110M by 2040 only add more pressure to innovate, not iterate.

So what does $30M really buy here? Distribution muscle, manufacturing scale, and the ability to move AlloFlo Uveo from a strong launch into a standard of care conversation. It also pushes pipeline assets like AlloSpan Canal further down the field, expanding Iantrek’s reach across both major outflow pathways.

Trinity Capital didn’t just write a check. They placed a bet on a company that understands something simple but overlooked. If you’re going to work on the human eye, you might want to respect how it was built in the first place.